Skip to main content
Retour
Watch Compare

Seres Therapeutics, Inc.

Qualité des données : 100%
MCRB
Nasdaq Manufacturing Chemicals
8,87 €
▲ 0,11 € (1,20%)
Cap. Boursière: 84,98 M
Prix
8,87 €
Cap. Boursière
84,98 M
Fourchette du Jour
8,58 € — 9,18 €
Fourchette 52 Semaines
6,53 € — 29,98 €
Volume
8 303
Ouverture 8,91 €
Moyenne 50J / 200J
10,48 €
15,40% below
Moyenne 50J / 200J
14,74 €
39,88% below

Quick Summary

Points Clés

Revenue declined -72,84% annually over 5 years
Earnings grew 4088,24% over the past year
ROE of 14,86% — decent returns on equity
Net margin of 721,93% shows strong profitability
Generating 865 000,0 in free cash flow
P/E of 14,92 — trading at a low valuation

Croissance

Revenue Growth (5Y)
-72,84%
En dessous de la moyenne du secteur (9,35%)
Revenue (1Y)N/A
Earnings (1Y)4088,24%
FCF Growth (3Y)N/A

Qualité

Return on Equity
14,86%
Au-dessus de la moyenne du secteur (-51,02%)
ROIC-63,48%
Net Margin721,93%
Op. Margin-11910,14%

Sécurité

Debt / Equity
N/A
Current Ratio2,30
Interest CoverageN/A

Valorisation

PE (TTM)
14,92
Au-dessus de la moyenne du secteur (-1,98)
P/B Ratio1,94
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (44 pairs)
Métrique Action Médiane du Secteur
P/E 14,9 -2,0
P/B 1,9 5,1
ROE % 14,9 -51,0
Net Margin % 721,9 -150,2
Rev Growth 5Y % -72,8 9,3
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) -92,10%
Earnings Growth (1Y) 4088,24% Earnings Growth (3Y) N/A
Revenue Growth (5Y) -72,84% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 789 000,0 Net Income (TTM) 5,70 M
ROE 14,86% ROA 3,97%
Gross Margin N/A Operating Margin -11910,14%
Net Margin 721,93% Free Cash Flow (TTM) 865 000,0
ROIC -63,48% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,30
Interest Coverage N/A Asset Turnover 0,01
Working Capital 29,10 M Tangible Book Value 43,70 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 14,92 Forward P/E N/A
P/B Ratio 1,94 P/S Ratio 107,71
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 1,02%
Market Cap 84,98 M Enterprise Value 37,34 M
Per Share
EPS (Diluted TTM) 0,64 Revenue / Share 0,08
FCF / Share 0,09 OCF / Share 0,12
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 31,94% FCF Conversion 15,19%
SBC-Adj. FCF -11,96 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 789 000,0 — 126,33 M 7,13 M 144,93 M
Net Income 5,70 M 136 000,0 -113,72 M -250,16 M -65,58 M
EPS (Diluted) 0,64 0,00 -0,89 -2,31 —
Gross Profit — — — — —
Operating Income -93,97 M -121,32 M -107,98 M -246,49 M -64,49 M
EBITDA — — — — —
R&D Expenses 49,06 M 64,60 M 145,86 M 172,92 M 141,89 M
SG&A Expenses — — — — —
D&A 4,13 M 5,47 M 6,24 M 6,63 M 5,95 M
Interest Expense 0,0 0,0 13,18 M 6,02 M 2,91 M
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 138,19 M 139,81 M 358,60 M 348,78 M 354,86 M
Total Liabilities 93,98 M 126,03 M 403,46 M 338,00 M 223,35 M
Shareholders' Equity 44,22 M 13,78 M -44,86 M 10,78 M 131,51 M
Total Debt — — 110,00 M 50,00 M 24,05 M
Cash & Equivalents 45,77 M 30,79 M 127,97 M 163,03 M 180,00 M
Current Assets 49,38 M 38,67 M 175,41 M 194,76 M 303,63 M
Current Liabilities 19,32 M 41,22 M 98,66 M 85,60 M 82,26 M